PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE espond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
				Application Number	10/594,773	
INFORMATION DISCLOSURE				Filing Date	September 29, 2006	7
S1	STATEMENT BY APPLICANT			First Named Inventor	Hiroshi Inooka	
				Art Unit	N/A 1646	1
(Use as many sheets as necessary)			necessary)	Examiner Name	Not Yet Assigned Ruixiang	L
Sheet	1	of	1	Attorney Docket Number	66368(46590)	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

		FOREI	GN PATENT	DOCUMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	l . l
	BA	WO-91/12022	08-22-1991	Takeda Chemical Industries, Ltd.		
	BB	WO-91/14786	10-03-1991	Takeda Chemical Industries, Ltd.		
	ВС	WO-2005/094881 A1	13.10.2005	Takeda Pharmaceutical Co., Ltd.		
	BD	WO-85/00974	14.03.1985	Hybritech., Inc.		\Box
	BE	WO-96/00284	04.01.96	Behringwerke Aktiengesellschaft		\Box
	BF	EP-0 467 416 A1	22.01.1992	Hybritech, Inc.		\bigcap
	BG	EP-0 298 654 B1	01.06.1994	Hybrisens, Ltd.		\Box
	ВН	JP-04-120025	21.04.1992	Tosoh Corp et al.		
	ВІ	WO-85/00974 (JP-60-502104)	14.03.1985	Hybritech, Inc.		
	BJ	JP-01-138 461 A2	05-31-1989	Hybrisens, Ltd.		\Box
	ВК	JP-03-133378 (US 5,660,978)	08-26-1997	Kwan et al.		
	BL	JP-10-504708 (US 6,010,868)	01-04-2000	Neuenhofer et a.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\)Applicant's unique citation designation number (optional). \(^2\)See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \(^3\)Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\)For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\)Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^6\)Applicant is to place a check mark here if English language Translation is attached. Translation is attached.

	NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	* magazine journal serial symposium catalog etc.) data paga(s) volume jague number/		T ²			
	CA	Suzuki, et al. (1993) Production of Immunoreactive Pituitary Adenylate Cyclase Activiting Polypeptide (PACAP) by Human Neuroblastoma Cells, IMR-32: Detection and Characterization with Monoclonal and Polyclonal Antibodies Against Different Epitocpes of PACAP. <i>J. Biochem, 113</i> , 549-556.				

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner	/my 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	Date	12/19/2008
Signature	/Huixiang Li/	Considered	12/10/2000
607499		Contraction	